The molecular biology of cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Aas, 1996, Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients, Nat. Med., 2, 811, 10.1038/nm0796-811
Aguilar, 1994, Geographic variation of p53 mutational profile in nonmalignant human liver, Science, 264, 1317, 10.1126/science.8191284
Alizadeh, 2000, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, 403, 503, 10.1038/35000501
Allgayer, 2000, c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems, J. Clin. Oncol., 18, 2201, 10.1200/JCO.2000.18.11.2201
Alon, 1999, Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays, Proc. Natl. Acad. Sci. USA, 96, 6745, 10.1073/pnas.96.12.6745
Ames, 1984, The detection of environmental mutagens and potential carcinogens, Cancer, 53, 2034, 10.1002/1097-0142(19840515)53:10<2034::AID-CNCR2820531005>3.0.CO;2-S
Ames, 1986, Food constituents as a source of mutagens, carcinogens, and anticarcinogens, Prog. Clin. Biol. Res., 206, 3
Ames, B.N., Gold, L.S., 1991. Mitogenesis, mutagenesis, and animal cancer tests. In: Chemically Induced Cell Proliferation: Implications for Risk Assessment. Wiley, New York, pp. 1–20
Ames, 1993, DNA lesions, inducible DNA repair, and cell division: three key factors in mutagenesis and carcinogenesis, Environ. Health Perspect., 101, 35, 10.2307/3431840
Anderson, 1993, Tumor suppressor genes studied by cell hybridization and chromosome transfer, FASEB J., 7, 826, 10.1096/fasebj.7.10.8344482
Artandi, 2000, Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice, Nature, 406, 641, 10.1038/35020592
Ashkenazi, 1999, Apoptosis control by death and decoy receptors, Curr. Opin. Cell Biol., 11, 255, 10.1016/S0955-0674(99)80034-9
Bachor, 1999, Telomerase is active in normal gastrointestinal mucosa and not up-regulated in precancerous lesions, J. Cancer Res. Clin. Oncol., 125, 453, 10.1007/s004320050302
Barker, 2000, The Yin-Yang of TCF/beta-catenin signaling, Adv. Cancer Res., 77, 1, 10.1016/S0065-230X(08)60783-6
Beerheide, 2000, Downregulation of proapoptotic proteins Bax and Bcl-X(S) in p53 overexpressing hepatocellular carcinomas, Biochem. Biophys. Res. Commun., 273, 54, 10.1006/bbrc.2000.2891
Bemark, 2000, The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line, Oncogene, 19, 3404, 10.1038/sj.onc.1203686
Bertram, 1974, Cell cycle dependency of oncogenic transformation induced by N-methyl-n'-nitro-N-nitrosoguanidine in culture, Cancer Res., 34, 526
Black, 1994, Platelet-derived growth factor expression and stimulation in human meningiomas, J. Neurosurg., 81, 388, 10.3171/jns.1994.81.3.0388
Boehm, 1997, Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, Nature, 390, 404, 10.1038/37126
Bookstein, 1990, Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene, Science, 247, 712, 10.1126/science.2300823
Bos, 1989, ras Oncogenes in human cancer: a review, Cancer Res., 49, 4682
Botchkarev, 2000, p53 is essential for chemotherapy-induced hair loss, Cancer Res., 60, 5002
Branford, 1999, Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics, Br.J. Haematol., 107, 587, 10.1046/j.1365-2141.1999.01749.x
Brehm, 1998, Retinoblastoma protein recruits histone deacetylase to repress transcription, Nature, 391, 597, 10.1038/35404
Brekken, 2000, Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice, Cancer Res., 60, 5117
Browder, 2000, Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer, Cancer Res., 60, 1878
Bunz, 1999, Disruption of p53 in human cancer cells alters the responses to therapeutic agents, J. Clin. Invest., 104, 263, 10.1172/JCI6863
Cahill, 1999, Genetic instability and darwinian selection in tumours, Trends Cell Biol., 9, M57, 10.1016/S0962-8924(99)01661-X
Cardone, 1997, The regulation of anoikis: MEKK-1 activation requires cleavage by caspases, Cell, 90, 315, 10.1016/S0092-8674(00)80339-6
Carrier, 1999, Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin, Mol. Cell Biol., 19, 1673, 10.1128/MCB.19.3.1673
Castaigne, 1992, A PML/retinoic acid receptor α fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia, Blood, 79, 3110, 10.1182/blood.V79.12.3110.3110
Castaigne, 1990, All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results, Blood, 76, 1704, 10.1182/blood.V76.9.1704.1704
Chan, 1998, Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis, Proc. Natl. Acad. Sci. USA, 95, 681, 10.1073/pnas.95.2.681
Chehab, 2000, Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53, Genes Dev., 14, 278, 10.1101/gad.14.3.278
Chen, 2000, Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin, Hum. Gene Ther., 11, 1983, 10.1089/10430340050143417
Chen, 1999, Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase, Cell, 98, 675, 10.1016/S0092-8674(00)80054-9
Chen, 1991, Rearrangements in the second intron of the RARA gene are present in a large majority of patients with acute promyelocytic leukemia and are used as molecular marker for retinoic acid-induced leukemic cell differentiation, Blood, 78, 2696, 10.1182/blood.V78.10.2696.2696
Chen, 1999, Chew. Emerging roles of BRCA1 in transcriptional regulation and DNA repair, J. Cell Physiol., 181, 385, 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4
Cheng, 1992, 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G–T and A–C substitutions, J. Biol. Chem., 267, 166, 10.1016/S0021-9258(18)48474-8
Cho, 1992, Genetic alterations in the adenoma–carcinoma sequence, Cancer, 70, 1727, 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P
Cho, 1994, Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations, Science, 265, 346, 10.1126/science.8023157
Clark, 2000, Genomic analysis of metastasis reveals an essential role for RhoC, Nature, 406, 532, 10.1038/35020106
Classon, 2000, Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control, Proc. Natl. Acad. Sci. USA, 97, 10820, 10.1073/pnas.190343497
Claudio, 2000, Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer, Cancer Res., 60, 372
Clayman, 2000, The current status of gene therapy, Semin. Oncol., 27, 39
Clayman, 2000, The current status of gene therapy, Semin. Oncol., 27, 39
Clayman, 1999, Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers, Clin. Cancer Res., 5, 1715
Cleaver, 1975, Xeroderma pigmentosum: biochemical and genetic characteristics, Annu. Rev. Genet., 9, 19, 10.1146/annurev.ge.09.120175.000315
M.S, 2000, Regulation of p53 stability and activity in response to genotoxic stress, Mutat. Res., 462, 179, 10.1016/S1383-5742(00)00035-1
Cory, 1999, Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation, Cancer Res., 59, 1685s
Costantini, 2000, Mitochondrion as a novel target of anticancer chemotherapy, J. Natl. Cancer Inst., 92, 1042, 10.1093/jnci/92.13.1042
Counter, 1997, The catalytic subunit of yeast telomerase, Proc. Natl. Acad. Sci. USA, 94, 9202, 10.1073/pnas.94.17.9202
Daley, 1990, Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome, Science, 247, 824, 10.1126/science.2406902
Doll, 1981, R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today, J. Natl. Cancer Inst., 66, 1191, 10.1093/jnci/66.6.1192
Druker, B.J., 1999. Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia. Am. Soc. Hematol. Abstract
Earnshaw, 1999, Mammalian caspases: structure, activation, substrates, and functions during apoptosis, Annu. Rev. Biochem., 68, 383, 10.1146/annurev.biochem.68.1.383
Eastham, 2000, Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer, J. Urol., 164, 814, 10.1016/S0022-5347(05)67320-X
El Deiry, 1994, WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis, Cancer Res., 54, 1169
W.S, 1993, WAF1, a potential mediator of p53 tumor suppression, Cell, 75, 817, 10.1016/0092-8674(93)90500-P
Feldman, 2000, Progress in antiangiogenic gene therapy of cancer, Cancer, 89, 1181, 10.1002/1097-0142(20000915)89:6<1181::AID-CNCR1>3.0.CO;2-T
Fraser, 1989, Second malignancies following cancer therapy, Semin. Oncol. Nurs., 5, 43, 10.1016/0749-2081(89)90022-3
Frosina, 2000, Overexpression of enzymes that repair endogenous damage to DNA, Eur. J. Biochem., 267, 2135, 10.1046/j.1432-1327.2000.01266.x
Galaktionov, 1996, Cdc25 cell-cycle phosphatase as a target of c-myc, Nature, 382, 511, 10.1038/382511a0
Gallie, 1999, Developmental basis of retinal-specific induction of cancer by RB mutation, Cancer Res., 59, 1731s
Goodwin, E.C., Yang, E., Lee, C.J., Lee, H.W., DiMaio, D., Hwang, E.S., 2000. Rapid induction of senescence in human cervical carcinoma cells [In Process Citation]. Proc. Natl. Acad. Sci. USA 97, 10978–10983
Greenblatt, 1994, Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis, Cancer Res., 54, 4855
Grignani, 1998, Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia, Nature, 391, 815, 10.1038/35901
Gu, 2000, Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers, Cancer Res., 60, 5359
Guo, 2000, Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma, Clin. Cancer Res., 6, 718
Guo, 1992, The gap-junctional protein connexin 43 is expressed in dermis and epidermis of human skin: differential modulation by retinoids, J. Invest. Dermatol., 99, 460, 10.1111/1523-1747.ep12616154
Hahn, 1999, Inhibition of telomerase limits the growth of human cancer cells, Nat. Med., 5, 1164, 10.1038/13495
Hahnfeldt, 1999, Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy, Cancer Res., 59, 4770
Hall, 1999, Radiation, DNA damage and cancer, Mol. Med. Today, 5, 157, 10.1016/S1357-4310(99)01435-5
Harbour, 1999, Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1, Cell, 98, 859, 10.1016/S0092-8674(00)81519-6
Harty, 1996, p53 mutations and occupational exposures in a surgical series of lung cancers, Cancer Epidemiol. Biomarkers Prev., 5, 997
He, 1998, Distinct interactions of PML-RAR α and PLZF-RAR α with co-repressors determine differential responses to RA in APL, Nature Genet., 18, 126, 10.1038/ng0298-126
Hecht, 1997, Approaches to cancer prevention based on an understanding of N-nitrosamine carcinogenesis, Proc. Soc. Exp. Biol. Med., 216, 181, 10.3181/00379727-216-44168
Henderson, 2000, Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover, Nat. Cell Biol., 2, 653, 10.1038/35023605
Hendry, 1991, The slower cellular recovery after higher-LET irradiations, including neutrons, focuses on the quality of DNA breaks, Radiat. Res., 128, S111, 10.2307/3578011
Hirao, 2000, DNA damage-induced activation of p53 by the checkpoint kinase Chk2, Science, 287, 1824, 10.1126/science.287.5459.1824
Huang, 1988, Use of all- trans retinoic acid in the treatment of acute promyelocytic leukemia, Blood, 72, 567, 10.1182/blood.V72.2.567.567
Jacoby, 2000, The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis, Cancer Res., 60, 5040
Jeffrey, 1977, Structures of benzoapyrene–nucleic acid adducts formed in human and bovine bronchial explants, Nature, 269, 348, 10.1038/269348a0
Jin, 2000, The GADD45 inhibition of Cdc2 kinase correlates with GADD45-mediated growth suppression, J. Biol. Chem., 275, 16602, 10.1074/jbc.M000284200
Kaban, 1999, Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a, Pediatrics, 103, 1145, 10.1542/peds.103.6.1145
Kagawa, 2000, Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines, Cancer Res., 60, 1157
Khuri, 2000, a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer, Nat. Med., 6, 879, 10.1038/78638
Khwaja, 1997, Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway, EMBO J., 16, 2783, 10.1093/emboj/16.10.2783
King, T.J., Fukushima, L.H., Hieber, A.D., Shimabukuro, K.A., Sakr, W.A., Bertram, J.S., 2000. Reduced levels of connexin43 in cervical dysplasia: inducible expression in a cervical carcinoma cell line decreases neoplastic potential with implications for tumor progression [In Process Citation]. Carcinogenesis 21, 1097–1109
Knudson, 1978, Retinoblastoma: a prototypic hereditary neoplasm, Semin. Oncol., 5, 57
Knudson, 1975, Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma, Proc. Natl. Acad. Sci. USA, 72, 5116, 10.1073/pnas.72.12.5116
Kondo, 2000, Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component, Oncogene, 19, 2205, 10.1038/sj.onc.1203538
Kroemer, 1999, Mitochondrial control of apoptosis: an overview, Biochem. Soc. Symp., 66, 1, 10.1042/bss0660001
Kushner, 2000, 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells, Gynecol. Oncol., 76, 183, 10.1006/gyno.1999.5668
Laird, 2000, SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors, Cancer Res., 60, 4152
Lakin, 1999, Regulation of p53 in response to DNA damage, Oncogene, 18, 7644, 10.1038/sj.onc.1203015
Lavin, 1999, ATM: the protein encoded by the gene mutated in the radiosensitive syndrome ataxia-telangiectasia, Int. J. Radiat. Biol., 75, 1201, 10.1080/095530099139359
Lawley, 1980, DNA as a target of alkylating carcinogens, Br. Med. Bull., 36, 19, 10.1093/oxfordjournals.bmb.a071608
Lawley, 1973, Methylation of DNA by 3H-14C-methyl-labelled N-methyl-N-nitrosourea–evidence for transfer of the intact methyl group, Chem. Biol. Interact., 7, 115, 10.1016/0009-2797(73)90020-3
le Coutre, 1999, In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor, J. Natl. Cancer Inst., 91, 163, 10.1093/jnci/91.2.163
Lebowitz, 1998, Non-Ras targets of farnesyltransferase inhibitors: focus on Rho, Oncogene, 17, 1439, 10.1038/sj.onc.1202175
Lee, 1991, Positive selection of candidate tumor-suppressor genes by subtractive hybridization, Proc. Natl. Acad. Sci. USA., 88, 2825, 10.1073/pnas.88.7.2825
Lehmann, 1977, Repair of ultraviolet light damage in a variety of human fibroblast cell strains, Cancer Res., 37, 904
Lemieux, 1989, First cytogenetic evidence of homozygosity for the retinoblastoma deletion in chromosome 13, Cancer Genet. Cytogenet., 43, 73, 10.1016/0165-4608(89)90129-5
Levine, 1997, p53, the cellular gatekeeper for growth and division, Cell, 88, 323, 10.1016/S0092-8674(00)81871-1
Li, 1996, Expression of the retinoblastoma (RB) tumor suppressor gene inhibits tumor cell invasion in vitro, Oncogene, 13, 2379
Li, 1999, Activation and targeting of immunoglobulin switch recombination by activities induced by EBV infection, J. Immunol., 163, 6659, 10.4049/jimmunol.163.12.6659
Lindahl, 1972, Rate of depurination of native deoxyribonucleic acid, Biochemistry, 11, 3610, 10.1021/bi00769a018
Loeb, 1991, Mutator phenotype may be required for multistage carcinogenesis, Cancer Res., 51, 3075
Lohmann, 1999, RB1 gene mutations in retinoblastoma, Hum. Mutat., 14, 283, 10.1002/(SICI)1098-1004(199910)14:4<283::AID-HUMU2>3.0.CO;2-J
Lowe, 1993, p53-dependent apoptosis modulates the cytotoxicity of anticancer agents, Cell, 74, 957, 10.1016/0092-8674(93)90719-7
Lynch, 1999, Genetic susceptibility to non-polyposis colorectal cancer, J. Med. Genet., 36, 801
Maecker, 2000, p53 promotes selection for Fas-mediated apoptotic resistance, Cancer Res., 60, 4638
Magee, 1972, Possibilities of hazard from nitrosamines in industry, Ann. Occup. Hyg., 15, 19, 10.1093/annhyg/15.1.19
Malkin, 1990, Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms, Sci., 250, 1233, 10.1126/science.1978757
Mancini, 1997, Constitutively methylated CpG dinucleotides as mutation hot spots in the retinoblastoma gene (RB1), Am J. Hum. Genet., 61, 80, 10.1086/513898
Marchenko, 2000, Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling, J. Biol. Chem., 275, 16202, 10.1074/jbc.275.21.16202
Marsters, 1999, Control of apoptosis signaling by Apo2 ligand, Recent Prog. Horm. Res., 54, 225
Mehta, 1986, Growth inhibition of transformed cells correlates with their junctional communication with normal cells, Cell, 44, 187, 10.1016/0092-8674(86)90497-6
Miller, 1975, Metabolic activation and reactivity of chemical carcinogens, Mutat. Res., 33, 25, 10.1016/0027-5107(75)90039-1
Minamoto, 2000, K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers–a review, Cancer Detect. Prev., 24, 1
Mirvish, S.S., 1995. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC [published erratum appears in Cancer Lett. 1995 Nov 6;97(2), 271]. Cancer Lett. 93, 17–48
Momand, 2000, MDM2–master regulator of the p53 tumor suppressor protein, Gene, 242, 15, 10.1016/S0378-1119(99)00487-4
Morin, 1999, beta-catenin signaling and cancer, Bioessays, 21, 1021, 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P
Mukai, 2000, 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas, Cancer Res., 60, 4461
Multani, 2000, Caspase-dependent apoptosis induced by telomere cleavage and TRF2 loss, Neoplasia, 2, 339, 10.1038/sj.neo.7900105
Nakashima, 2000, Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma, Head Neck, 22, 483, 10.1002/1097-0347(200008)22:5<483::AID-HED7>3.0.CO;2-H
Neve, 2000, Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells, Oncogene, 19, 1647, 10.1038/sj.onc.1203470
Neveu, 2000, Gap junctions and neoplasia, 221
Newbold, 1985, Multistep malignant transformation of mammalian cells by carcinogens: induction of immortality as a key event, Carcinog. Comput. Surv., 9, 17
Newbold, 1983, Fibroblast immortality is a prerequisite for transformation by EJc-Ha-ras oncogene, Nature, 304, 648, 10.1038/304648a0
O'Connell, 2000, Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict, Ann. NY Acad. Sci., 910, 178, 10.1111/j.1749-6632.2000.tb06708.x
O'Reilly, 1997, Endostatin: an endogenous inhibitor of angiogenesis and tumor growth, Cell, 88, 277, 10.1016/S0092-8674(00)81848-6
O'Reilly, 1996, Angiostatin induces and sustains dormancy of human primary tumors in mice, Nat. Med., 2, 689, 10.1038/nm0696-689
Overholt, 1997, Head and neck squamous cell growth suppression using adenovirus-p53-FLAG: a potential marker for gene therapy trials, Clin. Cancer Res., 3, 185
Owen-Schaub, 2000, Fas and Fas ligand interactions in malignant disease, Int. J. Oncol., 17, 5
Pappalardo, 1998, Microdissection, microchip arrays, and molecular analysis of tumor cells (primary and metastases), Semin. Radiat. Oncol., 8, 217, 10.1016/S1053-4296(98)80047-7
Parada, 1982, Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene, Nature, 297, 474, 10.1038/297474a0
Parada, 1983, Presence of a kirsten murine sarcoma virus ras oncogene in cells transformed by 3-methylcholanthrene, Mol. Cell. Biol., 3, 2298, 10.1128/MCB.3.12.2298
Pardee, 1974, A restriction point for control of normal animal cell proliferation, Proc. Natl. Acad. Sci. USA, 71, 1286, 10.1073/pnas.71.4.1286
Pegram, 2000, The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer, Cancer Treat. Res., 103, 57, 10.1007/978-1-4757-3147-7_4
Pegram, 1999, Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity, Semin. Oncol., 26, 89
Perletti, 2000, Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors, Cancer Res., 60, 1793
Pitti, 1998, Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer, Nature, 396, 699, 10.1038/25387
Prendergast, 1995, Critical role of Rho in cell transformation by oncogenic Ras, Oncogene, 10, 2289
Qiu, 1995, A role for Rho in Ras transformation, Proc. Natl. Acad. Sci. USA, 92, 11781, 10.1073/pnas.92.25.11781
Ramirez, 1999, Progressive increase in telomerase activity from benign melanocytic conditions to malignant melanoma, Neoplasia, 1, 42, 10.1038/sj.neo.7900004
Reed, 1997, Control of the G1/S transition, Cancer Surv., 29, 7
Reznikoff, 1973, Quantitative and qualitative studies of chemical transformation of cloned C3H mouse embryo cells sensitive to postconfluence inhibition of cell division, Cancer Res., 33, 2339
Roth, 1996, Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer, Nat. Med., 2, 985, 10.1038/nm0996-985
Rowinsky, 1999, Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development, J. Clin. Oncol., 17, 3631, 10.1200/JCO.1999.17.11.3631
Rusin, 1999, Molecular epidemiological study of non-small-cell lung cancer from an environmentally polluted region of Poland, Br. J. Cancer, 80, 1445, 10.1038/sj.bjc.6690542
Rytomaa, 2000, Matrix detachment induces caspase-dependent cytochrome c release from mitochondria: inhibition by PKB/Akt but not Raf signalling, Oncogene, 19, 4461, 10.1038/sj.onc.1203805
Sarvesvaran, 1999, Is small cell lung cancer the perfect target for anti-telomerase treatment?, Carcinogenesis, 20, 1649, 10.1093/carcin/20.8.1649
Sattler, 1997, Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL, Cytokine Growth Factor Rev., 8, 63, 10.1016/S1359-6101(96)00047-0
Scheffzek, 1997, The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants, Science, 277, 333, 10.1126/science.277.5324.333
Scheurle, 2000, HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test, Anticancer Res., 20, 2091
Schindler, 2000, Structural mechanism for STI-571 inhibition of abelson tyrosine kinase, Science, 289, 1938, 10.1126/science.289.5486.1938
Schuler, 1998, A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer, Hum. Gene Ther., 9, 2075, 10.1089/hum.1998.9.14-2075
Shields, 2000, Understanding Ras: `it ain't over 'til it's over', Trends Cell Biol., 10, 147, 10.1016/S0962-8924(00)01740-2
Shigenaga, 1989, Urinary -8-hydroxy-2′-deoxyguanosine as a biological marker of in vivo oxidative DNA damage, Proc. Natl. Acad. Sci. USA, 86, 9697, 10.1073/pnas.86.24.9697
Shih, 2000, The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression, Cancer Res., 60, 1671
Shinoura, 2000, Adenovirus-mediated transfer of p53 and Fas ligand drastically enhances apoptosis in gliomas, Cancer Gene Ther., 7, 732, 10.1038/sj.cgt.7700160
Shtutman, 1999, The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway, Proc. Natl. Acad. Sci. USA, 96, 5522, 10.1073/pnas.96.10.5522
Smith, 2000, p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes, Mol. Cell Biol., 20, 3705, 10.1128/MCB.20.10.3705-3714.2000
Croix, 2000, Genes expressed in human tumor endothelium, Science, 289, 1197, 10.1126/science.289.5482.1197
Stebbing, 2000, Herceptin (trastuzamab) in advanced breast cancer, Cancer Treat. Rev., 26, 287, 10.1053/ctrv.2000.0182
Strickland, 1983, Structure-activity relationships of a new series of retinoidal benzoic acid derivatives as measured by induction of differentiation of murine F9 teratocarcinoma cells and human HL-60 promyelocytic leukemia cells, Cancer Res., 43, 5268
Swisher, 1999, Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer, J. Natl. Cancer Inst., 91, 763, 10.1093/jnci/91.9.763
Takayama, 2000, Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ, Cancer Res., 60, 2169
Talpaz, C.L., 2000. Activity of an Abl specific tyrosine kinase inhibitor in patients with Bcr–Abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis. Am. Soc. Clin Oncology. (Abstract)
Tatsumoto, 2000, High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer, Clin. Cancer Res., 6, 2696
Templeton, 1991, Nonfunctional mutants of the retinoblastoma protein are characterized by defects in phosphorylation, viral oncoprotein association, and nuclear tethering, Proc. Natl. Acad. Sci. USA, 88, 3033, 10.1073/pnas.88.8.3033
Tetsu, 1999, Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells, Nature, 398, 422, 10.1038/18884
Thompson, 1995, Apoptosis in the pathogenesis and treatment of disease, Science, 267, 1456, 10.1126/science.7878464
Thompson, 2000, Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin, Cancer Res., 60, 3338
Tormo, 1998, Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation, Leuk. Lymphoma, 30, 367, 10.3109/10428199809057548
Tucker, 1988, Risk of second cancers after treatment for Hodgkin's disease, N. Engl. J. Med., 318, 76, 10.1056/NEJM198801143180203
Umbricht, 1999, Telomerase activity in ductal carcinoma in situ and invasive breast cancer, Oncogene, 18, 3407, 10.1038/sj.onc.1202714
van Steeg, 1999, Xeroderma pigmentosum and the role of UV-induced DNA damage in skin cancer, Mol. Med. Today, 5, 86, 10.1016/S1357-4310(98)01394-X
van Steensel, 1998, TRF2 protects human telomeres from end-to-end fusions, Cell, 92, 401, 10.1016/S0092-8674(00)80932-0
Vaux, 1988, Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells, Nature, 335, 440, 10.1038/335440a0
Vaziri, 1999, Alternative pathways for the extension of cellular life span: inactivation of p53/pRb and expression of telomerase, Oncogene, 18, 7676, 10.1038/sj.onc.1203016
Volpert, 1997, Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity, Oncogene, 14, 1495, 10.1038/sj.onc.1200977
vonLintig, 2000, Ras activation in human breast cancer, Breast Cancer Res. Treat., 62, 51, 10.1023/A:1006491619920
Vooijs, 1999, Developmental defects and tumor predisposition in Rb mutant mice, Oncogene, 18, 5293, 10.1038/sj.onc.1202999
Wang, 2000, Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells, Proc. Natl. Acad. Sci. USA, 97, 7124, 10.1073/pnas.97.13.7124
Wang, 2000, Li. The catalytic subunit of DNA-dependent protein kinase selectively regulates p53-dependent apoptosis but not cell-cycle arrest., Proc. Natl. Acad. Sci. USA, 97, 1584, 10.1073/pnas.97.4.1584
Watanabe, 2000, Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts, Proc. Natl. Acad. Sci. USA, 97, 8490, 10.1073/pnas.150104097
Weintraub, 1995, Mechanism of active transcriptional repression by the retinoblastoma protein, Nature, 375, 812, 10.1038/375812a0
Westermark, 1995, Platelet-derived growth factor in human glioma, Glia, 15, 257, 10.1002/glia.440150307
Westra, 1996, K-ras oncogene activation in atypical alveolar hyperplasias of the human lung, Cancer Res., 56, 2224
Wolf, 1998, Use of transgenic animals in understanding molecular mechanisms of toxicity, J. Pharm. Pharmacol., 50, 567, 10.1111/j.2042-7158.1998.tb06889.x
Wu, 1997, Suppression of tumor growth with recombinant murine angiostatin, Biochem. Biophys. Res. Commun., 236, 651, 10.1006/bbrc.1997.7032
Xiao, 2000, A DNA damage signal is required for p53 to activate gadd45, Cancer Res., 60, 1711
Yamauchi, 2000, Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer, J. Biol. Chem., 275, 33937, 10.1074/jbc.M000743200
Yashima, 1998, Expression of the RNA component of telomerase during human development and differentiation, Cell Growth Differ., 9, 805
Yen, 2000, Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis, Oncogene, 19, 3460, 10.1038/sj.onc.1203685
Zohn, 1998, Rho family proteins and Ras transformation: the RHOad less traveled gets congested, Oncogene, 17, 1415, 10.1038/sj.onc.1202181